FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1983669221> ?p ?o ?g. }

• W1983669221 endingPage "480" @default.
• W1983669221 startingPage "477" @default.
• W1983669221 abstract "Purpose Cryptococcus neoformans causes infections in up to 10 percent of patients with the acquired immunodeficiency syndrome (AIDS). Nearly 50 percent of AIDS patients with previously treated cryptococcal meningitis will experience a relapse within six months. To reduce the likelihood of relapse, a maintenance regimen of amphotericin B is often administered weekly. However, the drug's intravenous route of administration and considerable toxicity have led to a search for alternative antifungal agents. In this report, we document our experience with fluconazole, a new oral triazole antifungal agent. Patients and methods Twenty-two patients with AIDS and various forms of cryptococcosis were treated in an open-label study with 50 to 400 mg/day of fluconazole. The following laboratory studies were done on a monthly basis: complete blood cell count, liver function tests, serum creatinine level, serum cryptococcal antigen level, and serum fluconazole level. Lumbar puncture was performed in patients with meningitis every four to eight weeks to evaluate cerebrospinal fluid cryptococcal antigen, India ink preparation findings, fungal culture, fluconazole level, and protein, glucose, and cell count. Results Of seven patients with active culturepositive infections, four showed clinical and microbiologic responses (three of four with meningitis, one of three with extraneural cryptococcosis). Fifteen patients who had already undergone successful amphotericin B therapy for either meningitis (n = 14) or pneumonia (n = 1) received fluconazole as prophylaxis against relapse. Fourteen patients remained free of infection during 11 to 64 weeks of suppressive therapy; one patient with meningitis experienced relapse after 26 weeks of treatment. Adverse reactions were limited to increases in hepatic enzyme levels in four patients. Conclusion These results appear sufficiently encouraging to warrant further trials of this oral agent in the suppression of chronic cryptococcosis and perhaps in the treatment of acute infection. Cryptococcus neoformans causes infections in up to 10 percent of patients with the acquired immunodeficiency syndrome (AIDS). Nearly 50 percent of AIDS patients with previously treated cryptococcal meningitis will experience a relapse within six months. To reduce the likelihood of relapse, a maintenance regimen of amphotericin B is often administered weekly. However, the drug's intravenous route of administration and considerable toxicity have led to a search for alternative antifungal agents. In this report, we document our experience with fluconazole, a new oral triazole antifungal agent. Twenty-two patients with AIDS and various forms of cryptococcosis were treated in an open-label study with 50 to 400 mg/day of fluconazole. The following laboratory studies were done on a monthly basis: complete blood cell count, liver function tests, serum creatinine level, serum cryptococcal antigen level, and serum fluconazole level. Lumbar puncture was performed in patients with meningitis every four to eight weeks to evaluate cerebrospinal fluid cryptococcal antigen, India ink preparation findings, fungal culture, fluconazole level, and protein, glucose, and cell count. Of seven patients with active culturepositive infections, four showed clinical and microbiologic responses (three of four with meningitis, one of three with extraneural cryptococcosis). Fifteen patients who had already undergone successful amphotericin B therapy for either meningitis (n = 14) or pneumonia (n = 1) received fluconazole as prophylaxis against relapse. Fourteen patients remained free of infection during 11 to 64 weeks of suppressive therapy; one patient with meningitis experienced relapse after 26 weeks of treatment. Adverse reactions were limited to increases in hepatic enzyme levels in four patients. These results appear sufficiently encouraging to warrant further trials of this oral agent in the suppression of chronic cryptococcosis and perhaps in the treatment of acute infection." @default.
• W1983669221 created "2016-06-24" @default.
• W1983669221 creator A5020235374 @default.
• W1983669221 creator A5039293604 @default.
• W1983669221 creator A5060182938 @default.
• W1983669221 creator A5061649445 @default.
• W1983669221 creator A5080019231 @default.
• W1983669221 creator A5083418336 @default.
• W1983669221 creator A5086825885 @default.
• W1983669221 date "1988-10-01" @default.
• W1983669221 modified "2023-10-18" @default.
• W1983669221 title "Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: experience with 22 patients" @default.
• W1983669221 cites W1971219620 @default.
• W1983669221 cites W2007157395 @default.
• W1983669221 cites W2010915507 @default.
• W1983669221 cites W2011432259 @default.
• W1983669221 cites W2014696818 @default.
• W1983669221 cites W2016784435 @default.
• W1983669221 cites W2022188569 @default.
• W1983669221 cites W2062217860 @default.
• W1983669221 cites W2063947605 @default.
• W1983669221 cites W2080721443 @default.
• W1983669221 cites W2100037162 @default.
• W1983669221 cites W2138147795 @default.
• W1983669221 cites W2148014482 @default.
• W1983669221 cites W2319879113 @default.
• W1983669221 cites W3026406881 @default.
• W1983669221 doi "https://doi.org/10.1016/s0002-9343(88)80081-0" @default.
• W1983669221 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2845778" @default.
• W1983669221 hasPublicationYear "1988" @default.
• W1983669221 type Work @default.
• W1983669221 sameAs 1983669221 @default.
• W1983669221 citedByCount "149" @default.
• W1983669221 countsByYear W19836692212012 @default.
• W1983669221 countsByYear W19836692212013 @default.
• W1983669221 countsByYear W19836692212014 @default.
• W1983669221 countsByYear W19836692212015 @default.
• W1983669221 countsByYear W19836692212018 @default.
• W1983669221 crossrefType "journal-article" @default.
• W1983669221 hasAuthorship W1983669221A5020235374 @default.
• W1983669221 hasAuthorship W1983669221A5039293604 @default.
• W1983669221 hasAuthorship W1983669221A5060182938 @default.
• W1983669221 hasAuthorship W1983669221A5061649445 @default.
• W1983669221 hasAuthorship W1983669221A5080019231 @default.
• W1983669221 hasAuthorship W1983669221A5083418336 @default.
• W1983669221 hasAuthorship W1983669221A5086825885 @default.
• W1983669221 hasConcept C126322002 @default.
• W1983669221 hasConcept C141071460 @default.
• W1983669221 hasConcept C16005928 @default.
• W1983669221 hasConcept C203014093 @default.
• W1983669221 hasConcept C2777893358 @default.
• W1983669221 hasConcept C2778952914 @default.
• W1983669221 hasConcept C2779413141 @default.
• W1983669221 hasConcept C2779548794 @default.
• W1983669221 hasConcept C2779629538 @default.
• W1983669221 hasConcept C2779651940 @default.
• W1983669221 hasConcept C2780066322 @default.
• W1983669221 hasConcept C2780651595 @default.
• W1983669221 hasConcept C2780908437 @default.
• W1983669221 hasConcept C2781026528 @default.
• W1983669221 hasConcept C2781413609 @default.
• W1983669221 hasConcept C54355233 @default.
• W1983669221 hasConcept C71924100 @default.
• W1983669221 hasConcept C86803240 @default.
• W1983669221 hasConcept C89423630 @default.
• W1983669221 hasConcept C90924648 @default.
• W1983669221 hasConceptScore W1983669221C126322002 @default.
• W1983669221 hasConceptScore W1983669221C141071460 @default.
• W1983669221 hasConceptScore W1983669221C16005928 @default.
• W1983669221 hasConceptScore W1983669221C203014093 @default.
• W1983669221 hasConceptScore W1983669221C2777893358 @default.
• W1983669221 hasConceptScore W1983669221C2778952914 @default.
• W1983669221 hasConceptScore W1983669221C2779413141 @default.
• W1983669221 hasConceptScore W1983669221C2779548794 @default.
• W1983669221 hasConceptScore W1983669221C2779629538 @default.
• W1983669221 hasConceptScore W1983669221C2779651940 @default.
• W1983669221 hasConceptScore W1983669221C2780066322 @default.
• W1983669221 hasConceptScore W1983669221C2780651595 @default.
• W1983669221 hasConceptScore W1983669221C2780908437 @default.
• W1983669221 hasConceptScore W1983669221C2781026528 @default.
• W1983669221 hasConceptScore W1983669221C2781413609 @default.
• W1983669221 hasConceptScore W1983669221C54355233 @default.
• W1983669221 hasConceptScore W1983669221C71924100 @default.
• W1983669221 hasConceptScore W1983669221C86803240 @default.
• W1983669221 hasConceptScore W1983669221C89423630 @default.
• W1983669221 hasConceptScore W1983669221C90924648 @default.
• W1983669221 hasIssue "4" @default.
• W1983669221 hasLocation W19836692211 @default.
• W1983669221 hasLocation W19836692212 @default.
• W1983669221 hasOpenAccess W1983669221 @default.
• W1983669221 hasPrimaryLocation W19836692211 @default.
• W1983669221 hasRelatedWork W154087051 @default.
• W1983669221 hasRelatedWork W1856324556 @default.
• W1983669221 hasRelatedWork W1983669221 @default.
• W1983669221 hasRelatedWork W2011432259 @default.
• W1983669221 hasRelatedWork W2138482144 @default.
• W1983669221 hasRelatedWork W2418572412 @default.
• W1983669221 hasRelatedWork W2681165006 @default.

• next